Prospects for controlled-delivery systems.

Abstract

Americans seem to view medical progress as a citizen's entitlement. They expect, and researchers expect to seek, cures for acquired immunodeficiency syndrome (AIDS), Alzheimer's disease, cancer, and other deadly or incapacitating diseases. Both the public and researchers also seem undaunted by the cost. CDS technologies and biotechnology drugs are making this expectation possible. Still, CDSs may not dispel public resentment over the high cost--and profit--of discovering otherwise welcomed new healing molecules. As noted by 1988 Nobel laureate in medicine, Sir James Black: "I think both the press and industry have failed to communicate to the public that behind every little pill is a vast amount of high technology...." With increasing use of and satisfaction from CDSs, more of these mechanisms, covering a broadening spectrum of uses, will be marketed. Because these products are taken less often, patient compliance is expected to increase. As more CDSs are introduced, dispensing frequency will decline and the complexity of prescription drugs will increase. Pharmacists can take advantage of this trend by expanding their activities in the management their patients' medication use.